ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

CARD11-BCL10-MALT1 Complex Inhibitor XL114

Also written as “AUR104” and “XL114”.

Its studies are mostly in Lymphoma, Mantle-Cell, led by 2 companies.

Furthest: phase 1, since Dec 12, 20242 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Dr. Reddy's Laboratories10 open or runningphase 1since Dec 12, 2024Dec 12, 2024none ahead
Exelixis10 open or runningphase 1since Nov 10, 2021Nov 10, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 10, 2021First study: phase 1 study in Lymphoma, Non-HodgkinNew to ExelixisExelixis · NCT05144347 · 2 enrolled · United States
  2. Dec 12, 2024Dr. Reddy's Laboratories’ first study: phase 1 study in RecurrenceNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT06761586 · 9 enrolled · India

TargetBeta

“An orally bioavailable inhibitor of the caspase recruitment domain-containing protein 11 (CARD11; CARMA1)-B-cell lymphoma/leukemia 10 (BCL10)-mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) complex, ”NCIt, by rule

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06761586Recurrence · India1TerminatedDr. Reddy's LaboratoriesFeb 10, 20269
NCT05144347Lymphoma, Non-Hodgkin · United States1TerminatedExelixisNov 1, 20222

How it is read

Names in the registry

  • “AUR104”, 1 entry
  • “XL114”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.